Evidence map›Paper›PMID 39342365›Full record

ReviewJournal of experimental & clinical cancer research : CR2024

Focusing on CD8

Zhouchi Yao, Yayun Zeng, Cheng Liu, Huimin Jin, Hong Wang, Yue Zhang, Chengming Ding, Guodong Chen, Daichao Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. SPRED2 Negatively Regulates CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhouchi YaoDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Laboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Yayun ZengDepartment of Histology and Embryology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Cheng LiuDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Laboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Huimin JinDepartment of Histology and Embryology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Hong WangDepartment of Scientific Research, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Yue ZhangDepartment of Histology and Embryology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. 2021000048@usc.edu.cn.
Chengming DingDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Laboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. 2018011096@usc.edu.cn.
Guodong ChenDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Laboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. chenguodong@usc.edu.cn.
Daichao WuDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Laboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. wudaichao@usc.edu.cn.ORCID http://orcid.org/0000-0003-2086-0190

Funding

National Natural Science Foundation of China 32270995;32100985
6 · The paper itself

Abstract

Vigorous CD8

Indexed as

CD8-Positive T-LymphocytesNeoplasmsPhenotypeAnimalsHumansImmunotherapyTumor MicroenvironmentCD8+ T cellEngineered T cell receptor -T cellsGene editingImmune checkpointImmune reprogrammingImmunotherapyMetabolic reprogrammingSolid tumorT cell redirection

Identifiers

PMID39342365
PMCPMC11437975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.